The amount of an entity’s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 105
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 116
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_a&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_ContractLiabilities
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 113
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 114
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2021-01-01
-Paragraph 120
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_a&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Additional payment related to performance obligations received.

+ References

No definition available.

+ Details

Name:	imtx_AdditionalPaymentRelatedToPerformanceObligationsReceived
Namespace Prefix:	imtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Allocation of upfront payment towards clinical trial services.

+ References

No definition available.

+ Details

Name:	imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServices
Namespace Prefix:	imtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Allocation of upfront payment towards clinical trial services and license grant.

+ References

No definition available.

+ Details

Name:	imtx_AllocationOfUpfrontPaymentTowardsClinicalTrialServicesAndLicenseGrant
Namespace Prefix:	imtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Allocation of upfront payment towards license grant.

+ References

No definition available.

+ Details

Name:	imtx_AllocationOfUpfrontPaymentTowardsLicenseGrant
Namespace Prefix:	imtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development regulatory and commercial milestone payments receivable.

+ References

No definition available.

+ Details

Name:	imtx_DevelopmentRegulatoryAndCommercialMilestonePaymentsReceivable
Namespace Prefix:	imtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Disclosure of changes in accounting policies accounting estimates and errors.

+ References

No definition available.

+ Details

Name:	imtx_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsLineItems
Namespace Prefix:	imtx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone regulatory and royalty payment received.

+ References

No definition available.

+ Details

Name:	imtx_MilestoneRegulatoryAndRoyaltyPaymentReceived
Namespace Prefix:	imtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Receipt of upfront of payment.

+ References

No definition available.

+ Details

Name:	imtx_ReceiptOfUpFrontOfPayment
Namespace Prefix:	imtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue recognized during the period performance obligation.

+ References

No definition available.

+ Details

Name:	imtx_RevenueRecognizedDuringThePeriodPerformanceObligation
Namespace Prefix:	imtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront payment received.

+ References

No definition available.

+ Details

Name:	imtx_UpfrontPaymentReceived
Namespace Prefix:	imtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsBiotechnologiesGmbhMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imtx_AgreementAxis=imtx_LicenseDevelopmentAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=imtx_BristolMyerSquibCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=imtx_ImmaticsUsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imtx_AgreementAxis=imtx_AmendmentToTheStrategicCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imtx_AgreementAxis=imtx_BmsAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imtx_MilestoneAxis=imtx_DevelopmentRegulatoryAndCommercialMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=imtx_Ima401LicenseGrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_ProductsAndServicesAxis=imtx_Ima401ClinicalTrialServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant events and changes in the current reporting period - Additional information (Detail) € in Thousands, $ in Millions					3 Months Ended	6 Months Ended
	Jun. 01, 2022 USD ($)	Jun. 01, 2022 EUR (€)	Jan. 26, 2022 USD ($)	Jan. 26, 2022 EUR (€)	Jun. 30, 2022 EUR (€)	Jun. 30, 2022 EUR (€)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Mar. 31, 2022 USD ($)	Mar. 31, 2022 EUR (€)	Jan. 26, 2022 EUR (€)	Dec. 31, 2021 EUR (€)
Disclosure of changes in accounting policies accounting estimates and errors [line items]
Contract liabilities								€ 193,715				€ 98,627
Immatics Biotechnologies GmbH [member]
Disclosure of changes in accounting policies accounting estimates and errors [line items]
Transaction price allocation to performance obligation			$ 150								€ 133,000
License Development and Commercialization Agreement [member] \| Bristol Myer Squib Company [member] \| Immatics US Inc [member]
Disclosure of changes in accounting policies accounting estimates and errors [line items]
Upfront payment received	$ 60	€ 57,700
Additional payment related to performance obligations received	5	4,800
Milestone regulatory and royaly payment receivable \| $							$ 700
Transaction price allocation to performance obligation								60,700
Revenue recognized during the period performance obligation					€ 600
Amendment to the Strategic Collaboration Agreement [member] \| Bristol Myer Squib Company [member] \| Immatics Biotechnologies GmbH [member]
Disclosure of changes in accounting policies accounting estimates and errors [line items]
Upfront payment received	$ 20	€ 18,700
Transaction price allocation to performance obligation							$ 20	18,700
Revenue recognized during the period performance obligation					0
BMS Agreement [Member]
Disclosure of changes in accounting policies accounting estimates and errors [line items]
Contract liabilities								€ 42,000
BMS Agreement [Member] \| Immatics Biotechnologies GmbH [member]
Disclosure of changes in accounting policies accounting estimates and errors [line items]
Receipt of upfront of payment			150	€ 133,000
Allocation of upfront payment towards clinical trial services and license grant									$ 150	€ 133,000
Allocation of upfront payment towards clinical trial services										42,000
Allocation of upfront payment towards license grant										€ 91,000
BMS Agreement [Member] \| Immatics Biotechnologies GmbH [member] \| Development Regulatory and Commercial Milestone [Member]
Disclosure of changes in accounting policies accounting estimates and errors [line items]
Development regulatory and commercial milestone payments receivable \| $			$ 770
BMS Agreement [Member] \| Immatics Biotechnologies GmbH [member] \| IMA 401 License Grant [Member]
Disclosure of changes in accounting policies accounting estimates and errors [line items]
Revenue from contracts with customers						€ 91,000
BMS Agreement [Member] \| Immatics Biotechnologies GmbH [member] \| IMA 401 Clinical Trial Services [Member]
Disclosure of changes in accounting policies accounting estimates and errors [line items]
Revenue from contracts with customers					€ 2,800	€ 4,300